Alcon Call Center for Trial Locations
Fort Worth, Texas, 76134, United States
NCT Number: NCT00731640
Bilateral evaluation of unilateral implantation of ReSTOR and contralateral monofocal or phakic eye.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Fort Worth, Texas, 76134, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted
Time frame: 6 months
Uncorrected Visual Acuity (VA) is measured in logMAR. LogMAR is the "logarithm of the minimum angle of resolution". A lower logMAR value indicates better visual acuity.
Time frame: 6 Months
Contrast sensitivity is the measurement of one's ability to detect slight changes in luminance before it becomes indistinguishable. It is measured in logarithmic (log) units by means of an illuminated box, the CSV 1000 by Vector Vision. A higher value for the logarithmic units translates to better contrast sensitivity.
Time frame: 6 Months Postoperative
Average rating of patient satisfaction based on a patient survey. The survey had a 10 point scale (10 being most satisfied and 0 being most unsatisfied).
Time frame: 6 Months
The percentage of patients reporting spectacle independence (no longer needing to wear glasses).
Alcon Research
Industry
Clinical Outcomes With AcrySof ReSTOR Aspheric Apodized Diffractive Intraocular Lens (IOL) in One Eye and a Contralateral Monofocal IOL or Phakic Eye
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06377514
Cataract, Cataracts
Bakersfield, California, United States
View Trial DetailsNCT05575063
Cataract, Cataracts
Bakersfield, California, United States
View Trial DetailsNCT02535819
Cataract, Cataracts
Metz, France
View Trial DetailsNCT06250322
Cataract, Cataracts
Chatswood, New South Wales, Australia
View Trial Details